文献速递临床试验与 GCP

DIMS镜片与阿波罗渐进多焦镜片控制6-12岁儿童近视进展的多中心随机对照试验方案

Evaluating the myopia progression control efficacy of defocus incorporated multiple segments (DIMS) lenses and Apollo progressive addition spectacle lenses (PALs) in 6- to 12-year-old children: study protocol for a prospective, multicenter, randomized controlled trial.
PubMed 文献 · Trials · 2020-03-19

本研究为一项为期3年的前瞻性多中心随机对照试验,计划在中国招募600名6-12岁近视儿童,随机配戴DIMS镜片或阿波罗渐进多焦镜片(PALs),比较两组在睫状肌麻痹等效球镜度变化(主要结局)和眼轴长度(次要结局)上的差异,以评估两种近视离焦镜片的近视控制效果。

要点

  • 首个在中国近视小学生中比较DIMS与PALs的随机对照试验。
  • 主要结局为基线至末次随访的睫状肌麻痹等效球镜度变化。
  • 纳入标准为近视-1.00至-5.00 D,散光≤1.50 D。

核心结论

  • 该试验将首次在中国比较DIMS镜片与PALs对近视进展和眼轴延长的控制效果。
  • 结果将提供两种镜片的临床疗效、安全性及配戴体验信息。

研究设计与样本

  • 为期3年的前瞻性、多中心、随机对照临床试验。
  • 计划招募600名6-12岁中国小学生,每组拟纳入300名。
  • 随访时间点为1、3、6、12、18、24、30和36个月。

关键数值与推荐

  • 纳入标准:近视度数在-1.00至-5.00 D之间,散光≤1.50 D。
  • 主要结局:两组间基线至末次随访的睫状肌麻痹等效球镜度差异。
  • 次要结局:眼轴长度。
  • 探索性结局包括眼部生物测量、周边屈光、双眼视功能、调节、依从性及配戴体验问卷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myopia is increasing in prevalence and is currently recognized as a significant public health issue worldwide, particularly in China. Once myopia develops, appropriate clinical interventions need to be prescribed to slow its progression. Currently, several publications indicate that myopic defocus (MD) retards eye growth and myopia progression. However, no clinical trials have compared the outcomes of different MD spectacle lenses in the same observational group, especially in mainland China. The aim of the present study is to compare the myopia control efficiency of two different MD spectacle lenses: defocus incorporated multiple segments (DIMS) lenses and Apollo progressive addition lenses (PALs). METHODS: The trial is designed as a 3-year, prospective, randomized, multicenter clinical trial of schoolchildren treated with DIMS lenses and PALs. A total of 600 Chinese primary school children aged 6-12 years will be recruited, and each group is intended to include 300 subjects. The inclusion criteria are myopia between - 1.00 and - 5.00 diopters and astigmatism ≤ 1.50 diopters. The follow-up time points will be 1 month (m), 3 m, 6 m, 12 m, 18 m, 24 m, 30 m, and 36 m. The primary outcome will be determined by the difference between the two groups in cycloplegic spherical equivalent refraction between baseline and the last follow-up visit. The secondary outcome is the axial length, and the exploratory outcomes include ocular biometric measures, peripheral refraction, binocular vision, accommodation, compliance, and the results of questionnaires related to wearing experiences. DISCUSSION: The present study will be the first randomized controlled trial in myopic primary school children treated with DIMS lenses and PALs in China. The results will indicate whether and how much different MD mechanisms retard myopia progression and axial elongation. In addition, the comparison will provide information on the clinical efficacy and safety of DIMS lenses and PALs, including information related to wearing experiences and visual function. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR), ChiCTR1900025645. Registered on 3 September 2019. http://www.chictr.org.cn/showproj.aspx?proj=42927.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Li Y, Fu Y, Wang K, et al. Evaluating the myopia progression control efficacy of defocus incorporated multiple segments (DIMS) lenses and Apollo progressive addition spectacle lenses (PALs) in 6- to 12-year-old children: study protocol for a prospective, multicenter, randomized controlled trial. Trials. 2020. PMID: 32188478. doi:10.1186/s13063-020-4095-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。